{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:25:58Z","timestamp":1794288358236,"version":"4.9.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Progressive meningiomas present a significant therapeutic challenge; there are few therapeutic options in this scenario. Peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptors (SSTRs) is a promising strategy. This study, for the first time, evaluates the efficacy and safety of a combination or sequential use of alpha- emitting [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-DOTATATE and beta-emitting [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE PRRT for patients with advanced, refractory meningiomas.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      In this pilot study, 7 patients with inoperable or refractory meningiomas and high SSTR expression on [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTATATE PET\/CT were included. Patients received a median of 4 PRRT cycles, combining [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-DOTATATE and [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE. One patient received only\n                      <jats:sup>225<\/jats:sup>\n                      Ac-DOTATATE. The primary endpoint was progression-free survival (PFS) at 6 months following treatment using Response Assessment in Neuro-Oncology (RANO) criteria. Secondary endpoints included overall survival (OS), clinical response, imaging response, and toxicity. Imaging response was further assessed through semiquantitative analysis of pretreatment and posttreatment MRI and PET images. Single-lesion dosimetry was performed for 1 patient.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Our study achieved a PFS-6 rate of 85.7% (95% CI: 42.1%\u201399.6%). Of the 7 patients, 1 achieved complete clinical remission, 2 had partial remission, and 3 had stable disease. A median OS of 14 months (95% CI: 8\u201318\u00a0mo). At the lesion level (n = 25), responses were heterogeneous; SUVmax revealed partial response in 4 lesions, stable disease in 19, and progressive disease in 2. The therapy was well-tolerated, with only mild, grade 1 hematological toxicities observed. Single-lesion dosimetry calculated a tumor absorbed dose of 3.36 Gy\/MBq for [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-DOTATATE and 2.37 Gy\/GBq for [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Combined PRRT with\n                      <jats:sup>225<\/jats:sup>\n                      Ac\/\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTATATE appears feasible and potentially beneficial option in advanced meningiomas. However, given the small sample size, treatment heterogeneity, and lack of controlled comparison, the findings should be interpreted with caution. Larger prospective studies are warranted.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006536","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:11:49Z","timestamp":1782205909000},"page":"e865-e876","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Preliminary Evaluation of 225Ac\/177Lu-DOTATATE PRRT in Progressive Meningiomas"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7343-5564","authenticated-orcid":false,"given":"Reza","family":"Nemati","sequence":"first","affiliation":[{"name":"Department of Neurology, Bushehr Medical University Hospital, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik E.","family":"Juweid","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Division of Nuclear Medicine"},{"name":"The National Center for Diabetes, Endocrinology, and Genetics, University of Jordan, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9249-9248","authenticated-orcid":false,"given":"Esmail","family":"Jafari","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Molecular Imaging, and Theranostics, The Persian Gulf Nuclear Medicine Research Center, Bushehr Medical University Hospital, School of Medicine, Bushehr University of Medical Sciences, Bushehr"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Jokar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Molecular Imaging, and Theranostics, The Persian Gulf Nuclear Medicine Research Center, Bushehr Medical University Hospital, School of Medicine, Bushehr University of Medical Sciences, Bushehr"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Peer-Firozjaei","sequence":"additional","affiliation":[{"name":"Student Research Committee, Babol University of Medical Sciences, Babol"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Javad","family":"Rekabpour","sequence":"additional","affiliation":[{"name":"Department of Oncology, Salman Farsi Hospital, Bushehr, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7212-6521","authenticated-orcid":false,"given":"Felix M.","family":"Mottaghy","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"},{"name":"Center for Integrated Oncology (CIO), University Hospital RWTH Aachen, Aachen, Germany"},{"name":"Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2166-3765","authenticated-orcid":false,"given":"Majid","family":"Assadi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Molecular Imaging, and Theranostics, The Persian Gulf Nuclear Medicine Research Center, Bushehr Medical University Hospital, School of Medicine, Bushehr University of Medical Sciences, Bushehr"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"R1-20260908","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"R2-20260908","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/02688697.2019.1661965","article-title":"The outcome of patients with surgically treated meningioma in England: 1999\u20132013. a cancer registry data analysis","volume":"33","author":"Brodbelt","year":"2019","journal-title":"Br J Neurosurg"},{"key":"R3-20260908","first-page":"183","article-title":"Stereotactic radiosurgery for WHO II and III meningiomas: analysis of long-term clinical and radiographic outcomes","volume":"2","author":"Williams","year":"2013","journal-title":"J Radiosurg SBRT"},{"key":"R4-20260908","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro Oncol"},{"key":"R5-20260908","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/WCO.0000000000001002","article-title":"Chemotherapy and targeted therapies for meningiomas: what is the evidence?","volume":"34","author":"Graillon","year":"2021","journal-title":"Curr Opin Neurol"},{"key":"R6-20260908","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00259-019-04578-z","article-title":"An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy","volume":"47","author":"Assadi","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R7-20260908","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/RLU.0000000000003599","article-title":"Feasibility and therapeutic potential of peptide receptor radionuclide therapy for high-grade gliomas","volume":"46","author":"Nemati","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R8-20260908","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.21037\/qims.2019.08.16","article-title":"An update on PET-based molecular imaging in neuro-oncology: challenges and implementation for a precision medicine approach in cancer care","volume":"9","author":"Shooli","year":"2019","journal-title":"Quant Imaging Med Surg"},{"key":"R9-20260908","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cpet.2021.03.005","article-title":"Theranostics in brain tumors","volume":"16","author":"Shooli","year":"2021","journal-title":"PET Clinics"},{"key":"R10-20260908","first-page":"1538","article-title":"Somatostatin-receptor-targeted radionuclide therapy for progressive me ningioma: benefit linked to 68Ga-DOTATATE\/-TOC uptake","volume":"18","author":"Seystahl","year":"2016","journal-title":"Neuro Oncol"},{"issue":"suppl 1","key":"R11-20260908","first-page":"P1450","article-title":"Theragnostic for meningiomas: new benefits in molecular imaging.39. 225Ac-DOTATATE dosimetry results from part 1 of the ACTION-1 Trial","volume":"64","author":"Hernandez Ramirez","year":"2023","journal-title":"J Nucl Med"},{"key":"R12-20260908","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1007\/s00259-025-07075-8","article-title":"Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide the rapy targets in higher-grade meningioma","volume":"52","author":"Mair","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R13-20260908","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.3390\/curroncol29080438","article-title":"Somatostatin receptor theranostics for refractory meningiomas","volume":"29","author":"Salgues","year":"2022","journal-title":"Curr Oncol"},{"key":"R14-20260908","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4103\/wjnm.wjnm_39_18","article-title":"Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTAT ATE positron-emission tomography\/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of 177Lu-DOTAT ATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors","volume":"18","author":"Parghane","year":"2019","journal-title":"World J Nucl Med"},{"key":"R16-20260908","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2967\/jnumed.125.270115","article-title":"Retrospective evaluation of the correlation between somatostatin receptor PET\/CT and histopathology in patients with suspected intracranial meningiomas","volume":"66","author":"Ebner","year":"2025","journal-title":"J Nucl Med"},{"key":"R17-20260908","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/neuonc\/not330","article-title":"Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review","volume":"16","author":"Kaley","year":"2014","journal-title":"Neuro Oncol"},{"key":"R18-20260908","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/neuonc\/noy137","article-title":"Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group","volume":"21","author":"Huang","year":"2019","journal-title":"Neuro Oncol"},{"key":"R19-20260908","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","article-title":"3D Slicer as an image computing platform for the Quantitative Imaging Network","volume":"30","author":"Fedorov","year":"2012","journal-title":"Magn Reson Imaging"},{"key":"R20-20260908","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","article-title":"LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity","volume":"78","author":"Nioche","year":"2018","journal-title":"Cancer Res"},{"issue":"suppl 9","key":"R21-20260908","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1093\/neuonc\/noae069","article-title":"Radioligand therapies in meningioma: evidence and future directions","volume":"26","author":"Mair","year":"2024","journal-title":"Neuro Oncol"},{"key":"R22-20260908","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3390\/jcm11092364","article-title":"The current role of peptide receptor radionuclide therapy in meningiomas","volume":"11","author":"Fodi","year":"2022","journal-title":"J Clin Med"},{"key":"R23-20260908","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/neuonc\/noaf009","article-title":"Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: a RANO group systematic review and meta-analysis to guide clinical trial design","volume":"27","author":"Kotecha","year":"2025","journal-title":"Neuro Oncol"},{"key":"R24-20260908","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.2967\/jnumed.123.266956","article-title":"Peptide receptor radionuclide therapy in advanced refractory meningiom as: efficacy and toxicity in a long follow-up","volume":"65","author":"Severi","year":"2024","journal-title":"J Nucl Med"},{"key":"R25-20260908","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1053\/j.semnuclmed.2025.06.008","article-title":"Advances With (225)Ac-DOTATATE targeted alpha therapy in somatostatin receptor positive neuroendocrine tumors","volume":"55","author":"Chandekar","year":"2025","journal-title":"Semin Nucl Med"},{"key":"R26-20260908","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-23-2533","article-title":"Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma","volume":"30","author":"Kurz","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R29-20260908","doi-asserted-by":"crossref","first-page":"200782","DOI":"10.1016\/j.omton.2024.200782","article-title":"Noncoding RNA landscape and their emerging roles as biomarkers and therapeutic targets in meningioma","volume":"32","author":"Joshi","year":"2024","journal-title":"Mol Therap Oncol"},{"key":"R30-20260908","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/neuonc\/noae082","article-title":"Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients","volume":"26","author":"Wang","year":"2024","journal-title":"Neuro Oncol"},{"key":"R31-20260908","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3390\/life15040617","article-title":"An update on DOTA-peptides PET imaging and potential advancements of r adioligand therapy in intracranial meningiomas","volume":"15","author":"Benfante","year":"2025","journal-title":"Life"},{"key":"R32-20260908","doi-asserted-by":"crossref","first-page":"217","DOI":"10.23736\/S1824-4785.24.03571-4","article-title":"177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review","volume":"68","author":"Boursier","year":"2024","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R33-20260908","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.1007\/s00330-023-09697-8","article-title":"Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy","volume":"33","author":"Boursier","year":"2023","journal-title":"Eur Radiol"},{"key":"R34-20260908","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2967\/jnumed.114.147256","article-title":"Somatostatin receptor\u2013targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long -term results of a phase II clinical trial","volume":"56","author":"Marincek","year":"2015","journal-title":"J Nucl Med"},{"key":"R35-20260908","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1007\/s00259-024-06783-x","article-title":"Joint EANM\/EANO\/RANO\/SNMMI practice guideline\/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0","volume":"51","author":"Albert","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R36-20260908","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s41824-024-00204-w","article-title":"Clinical value of semi-quantitative parameters in 68Ga-DOTANOC PET\/CT in treatment and diagnostics of cranial meningioma in a single-center retrospective analysis","volume":"8","author":"Weitzer","year":"2024","journal-title":"EJNMMI Rep"},{"key":"R37-20260908","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00259-009-1115-z","article-title":"Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma","volume":"36","author":"Bartolomei","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R38-20260908","doi-asserted-by":"crossref","first-page":"035016","DOI":"10.1088\/1361-6560\/abd3ef","article-title":"Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow","volume":"66","author":"Tranel","year":"2021","journal-title":"Phys Med Biol"},{"issue":"suppl 1","key":"R39-20260908","first-page":"P129","article-title":"225Ac-DOTATATE dosimetry results from part 1 of the ACTION-1 Trial","volume":"64","author":"Sgouros","year":"2023","journal-title":"J Nucl Med"},{"key":"R40-20260908","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/s41388-020-01568-6","article-title":"The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges","volume":"40","author":"Fountain","year":"2021","journal-title":"Oncogene"},{"key":"R41-20260908","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00401-023-02635-4","article-title":"Normal meninges harbor oncogenic somatic mutations in meningioma-driver genes","volume":"146","author":"Boetto","year":"2023","journal-title":"Acta Neuropathol"},{"key":"R42-20260908","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1002\/cncr.35279","article-title":"Evolving concepts in meningioma management in the era of genomics","volume":"130","author":"Hsieh","year":"2024","journal-title":"Cancer"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:00:42Z","timestamp":1788901242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006536"}},"subtitle":["Efficacy, Dosimetry, and Imaging Insights"],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006536","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"2026-01-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}